4.3 Review

Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes

Journal

JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 26, Issue 4, Pages 329-334

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.3109/09546634.2014.991673

Keywords

Acitretin; ciclosporin; fumaric acid esters; methotrexate; pregnancy

Categories

Funding

  1. Abbott/AbbVie
  2. Almirall-Hermal
  3. Amgen
  4. BASF
  5. Biogen Idec
  6. Celgene
  7. Centocor
  8. Eli Lilly
  9. Forward Pharma
  10. Galderma
  11. Janssen
  12. Leo Pharma
  13. Medac
  14. MSD
  15. Miltenyi Biotech
  16. Novartis
  17. Pfizer
  18. Teva
  19. VBL
  20. Xenoport
  21. Abbvie
  22. Actelion
  23. GSK-Stiefel
  24. Sandoz
  25. Trident
  26. UCB

Ask authors/readers for more resources

The effects of conventional systemic therapies for psoriasis on pregnancy outcomes, lactation, male fertility and mutagenicity are common concerns in the clinical setting. There is relatively little evidence to guide clinician and patient. In this study, we review the safety profile of the commonly used conventional systemic therapies used for psoriasis in individuals of reproductive potential. Safety data are derived from large-scale registries, adverse-event reporting databases, clinical trials and case reports. We assess the effect of each therapy on adverse pregnancy outcomes, including congenital malformations, and lactation with maternal administration. We also assess the effect of the therapies on male fertility and potential mutagenicity with paternal administration. We provide applicable guidance to inform clinician and patient before and after conception.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available